Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
abbvie
allergan
ally bridge group
alzheimer's disease
big data analytics
blackrock
casdin capital
crispr
cynthia collins
deals
diabetic nephropathy
editas medicine
eventide asset management
focal segmental glomerulosclerosis
gene editing
goldfinch bio
irving investors
jay ghosh
leber congenital amaurosis type 10
michelle robertson
national top stories
parkinson's disease
rare diseases
san francisco blog main
schroeder adveq
software
third rock ventures
voyager therapeutics
wellington management company
yonjin capital
What
biotech
2
×
genetic
2
×
medicines
abbvie
alliance
analysis
bio
bring
company
develop
diseases
drug
editas
editing
employing
exits
experimental
gene
goldfinch
ipo
kidney
later
lead
million
new
pact
partnership
pruning
raised
raises
research
returning
rights
studies
terminated
treatment
Language
unset
Current search:
biotech
×
boston
×
genetic
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
